CAR T-Cell Therapy Research Updates | Dana-Farber Cancer Institute
CAR T-cell therapy is a powerful addition to cancer immunotherapy and has offered new hope to patients with certain blood cancers so far.
CAR T-cell therapy is a powerful addition to cancer immunotherapy and has offered new hope to patients with certain blood cancers so far.
18F-PSMA-1007 PET/CT generated superior locoregional staging results vs multiparametric MRI in patients with prostate cancer.
Sanjay K. Juneja, MD, delves into what being recognized as an oncology icon for Targeted Oncology means to him.
Concurrent radical cystectomy and extended lymph node dissection did not show benefit vs standard lymph node dissection in muscle invasive urothelial cancer.
Studies have suggested that 0.002% to 0.03% of NIPT results may indicate a possible maternal cancer. Among patients with malignancy-suspicious NIPT results, 6.4% to 73.0%…
This cohort study uses registry data to examine the risk of colorectal cancer (CRC) and CRC-specific death for up to 20 years after having a…
Melanoma of the Skin statistics
The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant…
Outcome improvements with lutetium Lu 177 vipivotide tetraxetan vs ARPI change favored prior treatment with abiraterone vs enzalutamide in mCRPC.
James Cribbin and his wife, Alexandra, came to MD Anderson for its expertise in marginal zone lymphoma, a rare subtype of non-Hodgkin lymphoma. What they…
Healio is accepting submissions for its third annual peer-recognition program, Healio Honors. The goal of the program is to celebrate health care professionals who go…